puromycin aminonucleoside has been researched along with ozagrel in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Harris, KP; Klahr, S; Lefkowith, JB; Schreiner, GF | 1 |
| Akama, H; Higuchi, E; Kamiyama, S; Kato, K; Kume, K; Ohara, N; Suzuki, H; Suzuki, J; Suzuki, S; Yugeta, E | 1 |
2 other study(ies) available for puromycin aminonucleoside and ozagrel
| Article | Year |
|---|---|
Essential fatty acid deficiency ameliorates acute renal dysfunction in the rat after the administration of the aminonucleoside of puromycin.
Topics: Acute Disease; Animals; Fatty Acids, Essential; Female; Kidney; Kidney Diseases; Leukopenia; Macrophages; Methacrylates; Nephrotic Syndrome; Puromycin Aminonucleoside; Rats; Rats, Inbred Lew; Thromboxane B2 | 1990 |
[Effects of a selective thromboxane A2 synthetase inhibitor, OKY-046, on proteinuria of aminonucleoside nephrotic rats].
Topics: Acrylates; Animals; Male; Methacrylates; Nephrotic Syndrome; Proteinuria; Puromycin Aminonucleoside; Rats; Rats, Inbred Strains; Thromboxane-A Synthase | 1988 |